HROW vs OCUL
HROW: Harrow is a commercial-stage ophthalmic pharmaceutical company dedicated to providing innovative eye care medications and solutions. OCUL: Ocular Therapeutix develops sustained-release, bioresorbable hydrogel-based ocular therapies to address chronic and acute eye diseases.
Side-by-side fundamentals
| Metric | HROW | OCUL | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $28.07 | $6.65 | |
| Market cap | $1.1B | $1.5B | |
| Net margin FY2025, SEC XBRL | -1.9% | -511.9% | HROW higher |
| Gross margin FY2025, SEC XBRL | +75.1% | n/a | |
| Operating margin FY2025, SEC XBRL | +11.2% | -519.8% | HROW higher |
| ROE FY2025, SEC XBRL | -9.8% | -40.6% | HROW higher |
| ROA FY2025, SEC XBRL | -1.3% | -32.9% | HROW higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +36.4% | -18.5% | HROW higher |
| Revenue CAGR (3y) SEC XBRL | +45.4% | +0.3% | HROW higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.46 | 1.35 | |
| 1-year return as of 2026-10-20 close | -33.4% | -45.4% | HROW higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.